gabapentin has been researched along with Delirium of Mixed Origin in 15 studies
Gabapentin: A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.
gabapentin : A gamma-amino acid that is cyclohexane substituted at position 1 by aminomethyl and carboxymethyl groups. Used for treatment of neuropathic pain and restless legs syndrome.
Excerpt | Relevance | Reference |
---|---|---|
"Although postoperative opioid use was reduced, perioperative administration of gabapentin did not result in a reduction of postoperative delirium or hospital length of stay." | 9.24 | Perioperative Gabapentin Does Not Reduce Postoperative Delirium in Older Surgical Patients: A Randomized Clinical Trial. ( Ames, C; Berven, S; Bozic, K; Burch, S; Chang, S; Chen, N; Chou, D; Covinsky, K; Deviren, V; Kinjo, S; Kramer, JH; Leung, JM; Meckler, G; Newman, S; Ries, M; Sands, LP; Tay, B; Tsai, T; Vail, T; Voss, V; Weinstein, P; Youngblom, E, 2017) |
"In this randomized pilot clinical trial, the authors tested the hypothesis that using gabapentin as an add-on agent in the treatment of postoperative pain reduces the occurrence of postoperative delirium." | 9.12 | Pilot clinical trial of gabapentin to decrease postoperative delirium in older patients. ( Ames, C; Chou, D; Dahl, JB; Leung, JM; Petersen, KL; Rico, M; Rowbotham, MC; Sands, LP; Weinstein, P, 2006) |
"Gabapentin (Neurontin) is approved by the US Food and Drug Administration for treatment of epilepsy and post-herpetic neuralgia." | 7.75 | Gabapentin-induced delirium and dependence. ( Kahn, DA; Kruszewski, SP; Paczynski, RP, 2009) |
"Although postoperative opioid use was reduced, perioperative administration of gabapentin did not result in a reduction of postoperative delirium or hospital length of stay." | 5.24 | Perioperative Gabapentin Does Not Reduce Postoperative Delirium in Older Surgical Patients: A Randomized Clinical Trial. ( Ames, C; Berven, S; Bozic, K; Burch, S; Chang, S; Chen, N; Chou, D; Covinsky, K; Deviren, V; Kinjo, S; Kramer, JH; Leung, JM; Meckler, G; Newman, S; Ries, M; Sands, LP; Tay, B; Tsai, T; Vail, T; Voss, V; Weinstein, P; Youngblom, E, 2017) |
"In this randomized pilot clinical trial, the authors tested the hypothesis that using gabapentin as an add-on agent in the treatment of postoperative pain reduces the occurrence of postoperative delirium." | 5.12 | Pilot clinical trial of gabapentin to decrease postoperative delirium in older patients. ( Ames, C; Chou, D; Dahl, JB; Leung, JM; Petersen, KL; Rico, M; Rowbotham, MC; Sands, LP; Weinstein, P, 2006) |
"In this cohort study, perioperative gabapentin use was associated with increased risk of delirium, new antipsychotic use, and pneumonia among older patients after major surgery." | 4.12 | Perioperative Gabapentin Use and In-Hospital Adverse Clinical Events Among Older Adults After Major Surgery. ( Bateman, BT; Inouye, SK; Kim, DH; Lee, SB; Levin, R; Lie, JJ; Marcantonio, ER; Metzger, E; Park, CM, 2022) |
"Gabapentin (Neurontin) is approved by the US Food and Drug Administration for treatment of epilepsy and post-herpetic neuralgia." | 3.75 | Gabapentin-induced delirium and dependence. ( Kahn, DA; Kruszewski, SP; Paczynski, RP, 2009) |
"Delirium is a very common and serious disorder with high morbidity and mortality." | 2.45 | Pharmacological treatment for the prevention of delirium: review of current evidence. ( Howard, R; Tabet, N, 2009) |
"Gabapentin is a second generation anticonvulsant that is effective in the treatment of chronic neuropathic pain." | 2.44 | Gabapentin: a multimodal perioperative drug? ( Irwin, MG; Kong, VK, 2007) |
"Infant delirium is an under-recognized clinical entity in neonatal intensive care, and earlier identification and treatment could minimize morbidities associated with this condition." | 1.46 | A case of infant delirium in the neonatal intensive care unit. ( Bidegain, M; Cotten, CM; Edwards, LE; Hornik, CD; Hutchison, LB; Smith, PB, 2017) |
"Delirium is still one of the most common and distressing symptoms in palliative care patients." | 1.38 | Reversible delirium in an advanced cancer patient. ( Jagsch, C; Kierner, KA; Watzke, HH, 2012) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 4 (26.67) | 29.6817 |
2010's | 8 (53.33) | 24.3611 |
2020's | 3 (20.00) | 2.80 |
Authors | Studies |
---|---|
Hilbert, MT | 1 |
Henkel, ND | 1 |
Spetz, SL | 1 |
Malaiyandi, DP | 1 |
Park, CM | 1 |
Inouye, SK | 1 |
Marcantonio, ER | 1 |
Metzger, E | 1 |
Bateman, BT | 1 |
Lie, JJ | 1 |
Lee, SB | 1 |
Levin, R | 1 |
Kim, DH | 1 |
Gupta, A | 1 |
Joshi, P | 1 |
Bhattacharya, G | 1 |
Lehman, M | 1 |
Funaro, M | 1 |
Tampi, DJ | 1 |
Tampi, RR | 1 |
Leung, JM | 2 |
Sands, LP | 2 |
Chen, N | 1 |
Ames, C | 2 |
Berven, S | 1 |
Bozic, K | 1 |
Burch, S | 1 |
Chou, D | 2 |
Covinsky, K | 1 |
Deviren, V | 1 |
Kinjo, S | 1 |
Kramer, JH | 1 |
Ries, M | 1 |
Tay, B | 1 |
Vail, T | 1 |
Weinstein, P | 2 |
Chang, S | 1 |
Meckler, G | 1 |
Newman, S | 1 |
Tsai, T | 1 |
Voss, V | 1 |
Youngblom, E | 1 |
Regan, DW | 1 |
Kashiwagi, D | 1 |
Dougan, B | 1 |
Sundsted, K | 1 |
Mauck, K | 1 |
Di Fabio, R | 1 |
D'Agostino, C | 1 |
Baldi, G | 1 |
Pierelli, F | 1 |
Salman, AE | 1 |
Camkıran, A | 1 |
Oğuz, S | 1 |
Dönmez, A | 1 |
Dighe, K | 1 |
Clarke, H | 1 |
McCartney, CJ | 1 |
Wong, CL | 1 |
Lee, YI | 1 |
Chen, L | 1 |
Smith, RL | 1 |
Edwards, LE | 1 |
Hutchison, LB | 1 |
Hornik, CD | 1 |
Smith, PB | 1 |
Cotten, CM | 1 |
Bidegain, M | 1 |
Tabet, N | 1 |
Howard, R | 1 |
Kruszewski, SP | 1 |
Paczynski, RP | 1 |
Kahn, DA | 1 |
Kierner, KA | 1 |
Jagsch, C | 1 |
Watzke, HH | 1 |
Rico, M | 1 |
Petersen, KL | 1 |
Rowbotham, MC | 1 |
Dahl, JB | 1 |
Kong, VK | 1 |
Irwin, MG | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Clinical Trial of Gabapentin to Decrease Postoperative Delirium and Pain in Surgical Patients[NCT00221338] | Phase 3 | 750 participants (Actual) | Interventional | 2006-01-31 | Completed | ||
The Preventative Role of Exogenous Melatonin Administration in Patients With Advanced Cancer Who Are at Risk of Delirium: a Feasibility Study Prior to a Larger Randomized Controlled Trial[NCT02200172] | Phase 2 | 60 participants (Actual) | Interventional | 2014-12-31 | Completed | ||
A Randomized, Double-blind, Placebo-controlled Trial to Assess the Safety and Efficacy of the Perioperative Administration of Pregabalin in Reducing the Incidence of Postoperative Delirium and Improving Acute Postoperative Pain Management[NCT00819988] | Phase 3 | 240 participants (Actual) | Interventional | 2009-05-31 | Completed | ||
Usefulness of Bright Light Therapy in the Prevention of Delirium in Patients Undergoing Hematopoietic Stem Cell Transplant (HSCT)[NCT01700816] | 40 participants (Actual) | Interventional | 2012-10-31 | Terminated (stopped due to Low incidence of delirium.) | |||
The Impact of Perioperative Gabapentin on Chronic Groin Pain After Inguinal Hernia Repair[NCT02419443] | Phase 4 | 100 participants (Anticipated) | Interventional | 2011-08-31 | Active, not recruiting | ||
Effect of Preoperative Pregabalin on Propofol Induction Dose[NCT01158859] | Phase 4 | 50 participants (Anticipated) | Interventional | 2010-04-30 | Completed | ||
The Effect of Gabapentin on Acute Pain and PONV in Bariatric Surgical Patients[NCT00886236] | 62 participants (Actual) | Interventional | 2008-02-29 | Completed | |||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
(NCT00221338)
Timeframe: Typically within the first week after surgery
Intervention | days (Mean) |
---|---|
Gabapentin | 4.4 |
Placebo | 4.1 |
Number of subjects who developed postoperative delirium, as measured by the Confusion Assessment Method, a validated tool for assessing delirium based on DSM-III-R, on any of the first three postoperative days. (NCT00221338)
Timeframe: postoperative days 1, 2 and 3
Intervention | Participants (Count of Participants) |
---|---|
Gabapentin | 84 |
Placebo | 72 |
Postoperative intravenous opioid doses converted to morphine equivalents. Median derived from total opioid doses on first, second and third postoperative days. (NCT00221338)
Timeframe: Study follow up period: postoperative days 1, 2 and 3
Intervention | morphine equivalents, mg (Median) |
---|---|
Gabapentin | 6.7 |
Placebo | 6.7 |
Postoperative pain as measured by Visual Analog Pain scale (0=no pain, 10=worst pain imaginable). (NCT00221338)
Timeframe: Postoperative day 1
Intervention | score on a scale (Mean) |
---|---|
Gabapentin | 4 |
Placebo | 4 |
Postoperative pain as measured by Visual Analog Pain scale (0=no pain, 10=worst pain imaginable). (NCT00221338)
Timeframe: Postoperative day 2
Intervention | score on a scale (Mean) |
---|---|
Gabapentin | 3 |
Placebo | 4 |
Postoperative pain as measured by Visual Analog Pain scale (0=no pain, 10=worst pain imaginable). (NCT00221338)
Timeframe: Postoperative day 3
Intervention | score on a scale (Mean) |
---|---|
Gabapentin | 3 |
Placebo | 3 |
Lab values at latest available follow-up date per participant. These tests are performed as part of routine clinical care on patients undergoing HSCT. (NCT01700816)
Timeframe: From admission to hospital to discharge, an expected average of 28 days post-transplant
Intervention | volume percentage (vol%) of red blood ce (Median) |
---|---|
Bright Light Therapy | 28.20 |
Sham Light | 26.70 |
Lab values at latest available follow-up date per participant. These tests are performed as part of routine clinical care on patients undergoing HSCT. (NCT01700816)
Timeframe: From admission to hospital to discharge, an expected average of 28 days post-transplant
Intervention | g/dl (Median) |
---|---|
Bright Light Therapy | 9.70 |
Sham Light | 9.55 |
(NCT01700816)
Timeframe: From admission to hospital to discharge, an expected average of 28 days post-transplant
Intervention | days (Median) |
---|---|
Bright Light Therapy | 18 |
Sham Light | 18.5 |
Monday, Wednesday, and Friday assessments will begin after beginning light therapy and include the Delirium Rating Scale-Revised-98 (DRS-98)and Memorial Delirium Assessment Scale (MDAS) (NCT01700816)
Timeframe: From hospital admission until the date of first documented delirium, assessed up to 28 days post-transplant
Intervention | Participants (Count of Participants) |
---|---|
Bright Light Therapy | 1 |
Sham Light | 0 |
Lab values at latest available follow-up date per participant. These tests are performed as part of routine clinical care on patients undergoing HSCT. (NCT01700816)
Timeframe: From admission to hospital to discharge, an expected average of 28 days post-transplant
Intervention | thousand cells/uL (Median) |
---|---|
Bright Light Therapy | 39 |
Sham Light | 33.5 |
Lab values at latest available follow-up date per participant. These tests are performed as part of routine clinical care on patients undergoing HSCT. (NCT01700816)
Timeframe: From admission to hospital to discharge, an expected average of 28 days post-transplant
Intervention | M/uL (Median) |
---|---|
Bright Light Therapy | 3.21 |
Sham Light | 2.93 |
"Monday, Wednesday, and Friday assessments of the Memorial Delirium Assessment Scale (MDAS); Patients will receive assessments after beginning light therapy until day 28 post-transplant or discharge, whichever comes first.~10 item scale Items are rated on a four-point scale from 0 (none) to 3 (severe) depending on the level of impairment, rendering a maximum possible score of 30.~A score of 13 has been recommended as a cut-off for establishing the diagnosis of delirium" (NCT01700816)
Timeframe: From first documented episode of delirium until discharge from the hospital, assessed up to 28 days post-transplant
Intervention | units on a scale (Number) |
---|---|
Bright Light Therapy | 18 |
Lab values at latest available follow-up date per participant. These tests are performed as part of routine clinical care on patients undergoing HSCT. (NCT01700816)
Timeframe: From admission to hospital to discharge, an expected average of 28 days post-transplant
Intervention | K/uL (Median) |
---|---|
Bright Light Therapy | 2.30 |
Sham Light | 4.75 |
Lab values at latest available follow-up date per participant. These tests are performed as part of routine clinical care on patients undergoing HSCT. (NCT01700816)
Timeframe: From admission to hospital to discharge, an expected average of 28 days post-transplant
Intervention | mg/dl (Median) | |
---|---|---|
Serum Creatinine | Blood Urea Nitrogen (BUN) | |
Bright Light Therapy | 0.66 | 9 |
Sham Light | 0.75 | 8.5 |
Lab values at latest available follow-up date per participant. These tests are performed as part of routine clinical care on patients undergoing HSCT (Hematopoietic Stem Cell Transplantation). (NCT01700816)
Timeframe: From admission to hospital to discharge, an expected average of 28 days post-transplant
Intervention | mmol/L (Median) | |||
---|---|---|---|---|
Sodium (Na) | Potassium (K) | Chloride (Cl) | Carbon Dioxide (CO2) | |
Bright Light Therapy | 139 | 3.6 | 105 | 24.9 |
Sham Light | 138.0 | 3.80 | 103.0 | 25.10 |
(NCT00886236)
Timeframe: 48 hours
Intervention | % oxygen saturation (Mean) |
---|---|
1 Preoperative Gabapentin Liquid | 93 |
2 Preoperative and Postoperative Gabapentin Liquid | 94 |
3 Preoperative and Postoperative Placebo Liquid | 95 |
The amount of intraoperative and postoperative opioids used will be collected and analyzed for the three different arms. (NCT00886236)
Timeframe: 120 hours
Intervention | ml (Mean) |
---|---|
1 Preoperative Gabapentin Liquid | 11.035 |
2 Preoperative and Postoperative Gabapentin Liquid | 8.7 |
3 Preoperative and Postoperative Placebo Liquid | 12.4 |
(NCT00886236)
Timeframe: 120 hours
Intervention | Participants (Count of Participants) |
---|---|
1 Preoperative Gabapentin Liquid | 12 |
2 Preoperative and Postoperative Gabapentin Liquid | 11 |
3 Preoperative and Postoperative Placebo Liquid | 12 |
4 reviews available for gabapentin and Delirium of Mixed Origin
Article | Year |
---|---|
Is there evidence for using anticonvulsants in the prevention and/or treatment of delirium among older adults?
Topics: Aged; Anticonvulsants; Arthroplasty, Replacement, Hip; Delirium; Gabapentin; Humans; Pregabalin | 2022 |
Update in perioperative medicine: practice changing evidence published in 2016.
Topics: Amines; Analgesics; Anticoagulants; Antipsychotic Agents; Arthritis, Rheumatoid; Blood Transfusion; | 2017 |
Pharmacological treatment for the prevention of delirium: review of current evidence.
Topics: Amines; Anti-Inflammatory Agents; Anticonvulsants; Antipsychotic Agents; Central Nervous System Depr | 2009 |
Gabapentin: a multimodal perioperative drug?
Topics: Amines; Analgesics, Non-Narcotic; Anti-Anxiety Agents; Blood Pressure; Chronic Disease; Cyclohexanec | 2007 |
Gabapentin: a multimodal perioperative drug?
Topics: Amines; Analgesics, Non-Narcotic; Anti-Anxiety Agents; Blood Pressure; Chronic Disease; Cyclohexanec | 2007 |
Gabapentin: a multimodal perioperative drug?
Topics: Amines; Analgesics, Non-Narcotic; Anti-Anxiety Agents; Blood Pressure; Chronic Disease; Cyclohexanec | 2007 |
Gabapentin: a multimodal perioperative drug?
Topics: Amines; Analgesics, Non-Narcotic; Anti-Anxiety Agents; Blood Pressure; Chronic Disease; Cyclohexanec | 2007 |
Gabapentin: a multimodal perioperative drug?
Topics: Amines; Analgesics, Non-Narcotic; Anti-Anxiety Agents; Blood Pressure; Chronic Disease; Cyclohexanec | 2007 |
Gabapentin: a multimodal perioperative drug?
Topics: Amines; Analgesics, Non-Narcotic; Anti-Anxiety Agents; Blood Pressure; Chronic Disease; Cyclohexanec | 2007 |
Gabapentin: a multimodal perioperative drug?
Topics: Amines; Analgesics, Non-Narcotic; Anti-Anxiety Agents; Blood Pressure; Chronic Disease; Cyclohexanec | 2007 |
Gabapentin: a multimodal perioperative drug?
Topics: Amines; Analgesics, Non-Narcotic; Anti-Anxiety Agents; Blood Pressure; Chronic Disease; Cyclohexanec | 2007 |
Gabapentin: a multimodal perioperative drug?
Topics: Amines; Analgesics, Non-Narcotic; Anti-Anxiety Agents; Blood Pressure; Chronic Disease; Cyclohexanec | 2007 |
4 trials available for gabapentin and Delirium of Mixed Origin
Article | Year |
---|---|
Perioperative Gabapentin Does Not Reduce Postoperative Delirium in Older Surgical Patients: A Randomized Clinical Trial.
Topics: Aged; Amines; Analgesics; Analgesics, Opioid; Cyclohexanecarboxylic Acids; Delirium; Double-Blind Me | 2017 |
Gabapentin premedication for postoperative analgesia and emergence agitation after sevoflurane anesthesia in pediatric patients.
Topics: Amines; Anesthesia, General; Anesthetics, Inhalation; Anti-Anxiety Agents; Child; Child, Preschool; | 2013 |
Perioperative gabapentin and delirium following total knee arthroplasty: a post-hoc analysis of a double-blind randomized placebo-controlled trial.
Topics: Aged; Amines; Analgesics; Arthroplasty, Replacement, Knee; Cyclohexanecarboxylic Acids; Delirium; Do | 2014 |
Pilot clinical trial of gabapentin to decrease postoperative delirium in older patients.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Delirium; Feasibility Studies; Female; Gabapentin; | 2006 |
Pilot clinical trial of gabapentin to decrease postoperative delirium in older patients.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Delirium; Feasibility Studies; Female; Gabapentin; | 2006 |
Pilot clinical trial of gabapentin to decrease postoperative delirium in older patients.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Delirium; Feasibility Studies; Female; Gabapentin; | 2006 |
Pilot clinical trial of gabapentin to decrease postoperative delirium in older patients.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Delirium; Feasibility Studies; Female; Gabapentin; | 2006 |
Pilot clinical trial of gabapentin to decrease postoperative delirium in older patients.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Delirium; Feasibility Studies; Female; Gabapentin; | 2006 |
Pilot clinical trial of gabapentin to decrease postoperative delirium in older patients.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Delirium; Feasibility Studies; Female; Gabapentin; | 2006 |
Pilot clinical trial of gabapentin to decrease postoperative delirium in older patients.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Delirium; Feasibility Studies; Female; Gabapentin; | 2006 |
Pilot clinical trial of gabapentin to decrease postoperative delirium in older patients.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Delirium; Feasibility Studies; Female; Gabapentin; | 2006 |
Pilot clinical trial of gabapentin to decrease postoperative delirium in older patients.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Delirium; Feasibility Studies; Female; Gabapentin; | 2006 |
7 other studies available for gabapentin and Delirium of Mixed Origin
Article | Year |
---|---|
The Rising Status of Phenobarbital: A Case for Use in Severe Refractory Hyperactive Poststroke Delirium.
Topics: Antipsychotic Agents; Delirium; Gabapentin; Hospitalization; Humans; Male; Middle Aged; Phenobarbita | 2023 |
Perioperative Gabapentin Use and In-Hospital Adverse Clinical Events Among Older Adults After Major Surgery.
Topics: Aged; Antipsychotic Agents; Cohort Studies; Delirium; Female; Gabapentin; Hospital Mortality; Hospit | 2022 |
Delirium after gabapentin withdrawal. Case report.
Topics: Aged; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Delirium; Electroencephalography; Epilep | 2013 |
Enigmatic Fever and Delirium in a Critically Ill Patient.
Topics: Adult; Amines; Critical Illness; Cyclohexanecarboxylic Acids; Delirium; Fever; Gabapentin; gamma-Ami | 2015 |
A case of infant delirium in the neonatal intensive care unit.
Topics: Amines; Analgesics, Opioid; Anti-Anxiety Agents; Cardiac Catheterization; Cyclohexanecarboxylic Acid | 2017 |
Gabapentin-induced delirium and dependence.
Topics: Adult; Amines; Analgesics, Non-Narcotic; Cyclohexanecarboxylic Acids; Delirium; Gabapentin; gamma-Am | 2009 |
Reversible delirium in an advanced cancer patient.
Topics: Amines; Analgesics; Analgesics, Opioid; Bone Neoplasms; Breast Neoplasms; Carcinoma, Intraductal, No | 2012 |